Indivumed GmbHThe Hamburg-based company Indivumed has repositioned itself, sending a clear message with a recent change in leadership: A new chapter is beginning with the focus on discovering and developing novel therapeutic targets for innovative cancer therapies. |transkript spoke with Prof. Dr. Hartmut Juhl and Dr. Matthias Evers.
Tag Archive for: AI
BioNTechBioNTech is set to open a research centre for cancer therapy in the United Kingdom, much to the delight of the British government, which is helping pave the way with a substantial financial boost.
Minos Biosciences SAOnly three weeks to go until Europe’s largest event for laboratory automation and drug screening. SLAS Europe 2025, organised by the Society for Laboratory Automation and Screening (SLAS), will take place in Hamburg from 20-22 May. In a series, European Biotechnology Magazine presents the 12 most innovative SMEs today: French Minos Biosciences SAS.
Tenthpin GroupThe much-discussed digital transformation in the healthcare sector is in full swing. European Biotechnology spoke with Dr. Sabrina Graf, COO of the globally active Tenthpin Group, about how the right software can improve quality management, keep the system landscape lean, and safe both, time and money.
Brainomix Ltd.University of Oxford spinout Brainomix Ltd has closed a £14m Series C round to advance its commercial expansion in the US. Funding will also support clinical uptake of its AI imaging technology in stroke and lung fibrosis.
Cradle.bioThe Dutch-Swiss company with operations also in Zurich, Switzerland, has raised US$73m in a Series B and will continue to expand its AI research, sales, and operations teams. The new announcement comes around a year after raising €21.92m in a Series A funding round.
BIOCOMBiotech CSOs, CDMOs, CROs, lab specialists and AI developers gave an in-depth insight into next-generation antibody-based therapies to about 1,500 attendees at the 16th PEGS Europe in Barcelona. Several new formats are expected to enter the market in the next few years, promising to significantly reduce the side effects of CAR-Ts, bispecific antibodies, ADCs, etc. and improve their efficacy.
Knowledge Seeker - wikipedia.orgDigital pathology specialist AIgnostics GmbH has topped up its cash position to US$55m with a US$34m Series B financing. The money will be used to optimise the company’s RudolfV Foundation Model and to develop and offer new services for target and biomarker identification selection, particularly in the US pharma market.
Ikerian AGSwiss Ikerian AG’s US-subsidiary, RetinAI U.S. Inc. has announced the first close of an CHF6.73m Series B financing with new and existing investors to advance its AI-based image analysis platform alongside a strategic partnership.
Molcure IncGerman antibody specialist YUMAB GmbH has inked a collaboration agreement with Japanese MOLCURE Inc aimed at using the company’s zero-shot AI technology for antibody discovery.